Evidence before commitment.

1. 01

   Manufacturer evaluation

   Can this manufacturer genuinely supply this product, at this volume, now?

   We evaluate manufacturer and product documentation against the requirements of the intended market before progressing a supply opportunity.

   We do not represent a manufacturer's capability until we have evaluated it.

2. 02

   Documentary readiness

   Do the necessary documents exist, and are they suitable for this market?

   Documentation is part of the product. A pharmaceutical supply opportunity is only as executable as the documentation supporting it.

   We establish documentary readiness before making commitments that depend on it.

3. 03

   Commercial coordination

   Are price, MOQ, lead time and payment structure executable, or only quotable?

   We compete seriously on price without buying a lower price through weaker quality, documentation, legality or supply sustainability.

   A quotation states price, MOQ, lead time, shelf life, Incoterm and payment structure, and names the assumptions it rests on.

4. 04

   Accountable execution

   Does communication stay aligned with production, documents and shipment from PO to delivery?

   We are accountable for our role in communication, coordination and resolution, from purchase order to delivery.

   When something changes, we tell you what changed, the revised expectation, what we are doing and when you will next hear from us.

Initial opportunity set

We are beginning international market development with Kenya, Tanzania, Uganda and Nigeria. These markets are not permanently ranked. Priority depends on six conditions:

• A credible buyer
• A usable regulatory route
• An appropriate manufacturer
• Acceptable payment risk
• Workable economics
• A realistic shipment timeline

An enquiry for any other market is assessed against the same six conditions.